Cover Image
市場調查報告書

血漿製劑的全球市場 (2015∼2019年)

Global Plasma Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336931
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
血漿製劑的全球市場 (2015∼2019年) Global Plasma Therapeutics Market 2015-2019
出版日期: 2015年08月05日 內容資訊: 英文 71 Pages
簡介

血漿為血液中的成分之一,是運送血液細胞和其他成分的手段。還有也發揮運送水分和鹽分、酵素,營養素,荷爾蒙等物質到體內各處這樣的作用。血漿中包含免疫球蛋白和凝血因子、其它物質成分,有助於治癒各種疾病。血漿採用血漿分離替換法從血液分離。血漿製劑用於各種難治之症和遺傳基因疾病 (免疫力缺乏、肺障礙、神經病變、休克症、外傷、肝硬化等)、感染疾病 (破傷風、肝炎、狂犬病(恐水症)等) 的治療。全球血漿製劑市場2014∼2019年預計以12.10%的年複合成長率(CAGR) 成長。

本報告提供全球血漿製劑 (血漿來源的治療藥) 的市場相關分析、產品概要、法規環境和基本的市場結構、市場規模趨勢 (今後5年的預測值)、各產品、各疾病、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 主要供應商的產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 血漿製劑概要

  • 血漿的成分
  • 血漿製劑的生成過程
  • 血漿臨床利用
  • 血漿製劑的成本結構

第6章 血漿製劑的相關法規

  • 法規當局

第7章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第8章 市場區分:各血漿分餾製劑

  • 人體血清蛋白
  • 血漿來源的凝血因子
  • 免疫球蛋白
  • 高免疫球蛋白
  • A1PI (α1蛋白酶抑制劑)
  • 全球人體血清蛋白市場 (今後6年份)
  • 全球免疫球蛋白市場 (今後6年份)
  • 全球A1PI市場 (今後6年份)

第9章 疾病的各種類的市場區隔

  • 凝固障礙
  • 免疫障礙
  • AATD (α1抗胰蛋白酶缺損症)
  • 其他

第10章 地區區分

第11章 市場成長的推動要素

第12章 推動因素與其影響力

第13章 市場課題

第14章 推動因素、課題的影響力

第15章 市場趨勢

第16章 供應商環境

  • 競爭方案
  • 市場佔有率分析
  • 其他卓越供應商

第17章 主要供應商分析

  • Baxter International Inc.
  • CSL Behring
  • Grifols
  • Octapharma

第18章 附錄

  • 簡稱集

圖表一覽

目錄
Product Code: IRTNTR6802

About plasma and plasma therapeutics

Plasma, pale yellow in color, is the component of the blood. It acts as a medium of transportation for the blood cells and other components. It carries salts and enzymes along with water and also transports nutrients, hormones, and other substances to the different parts of the body. Plasma contains immunoglobulins, clotting factors, albumin, and other components that can be used for the treatment of various diseases. The separation of plasma from the blood is done by a process known as plasmapheresis. Plasma therapeutics are utilized in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies.

Technavio's analysts forecast the global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI.

Technavio's report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • CSL Behring
  • Grifols Therapeutics
  • Octapharma

Other Prominent Vendors

  • Abeona Therapeutics
  • ADMA Biologics
  • Amag Pharmaceuticals
  • Antares Pharma
  • BioDelivery Sciences
  • Bio Products Laboratory
  • Biota Pharmaceuticals
  • Biotest Pharmaceuticals
  • China Biologic Products
  • Depomed
  • Emergent BioSolutions
  • Ethicon
  • Flamel Technologies
  • Kamada
  • Kedrion
  • King Pharmaceuticals
  • Nektar Therapeutics
  • OMRIX Biopharmaceuticals
  • ProMetic Life Sciences
  • Rockwell Medical
  • The Medicines
  • ZymoGenetics

Key market driver

  • Growing demand for IVIG therapies
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01:Executive summary

  • Highlights

PART 02:Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03:Market research methodology

  • Research methodology
  • Economic indicators

PART 04:Introduction

  • Key market highlights

PART 05:Plasma therapeutics: An overview:

  • Components of blood plasma
  • Process to derive plasma therapeutics
  • Clinical uses of plasma
  • Cost structure of plasma therapeutics

PART 06:Regulation of plasma therapeutics

  • Regulatory authorities

PART 07:Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08:Market segmentation by fractionation products of plasma

  • Human albumin
  • Plasma derived coagulation factors
  • Immunoglobulins
  • Hyperimmune globulins
  • A1PI
  • Global human albumin market 2014-2019
  • Global immunoglobulins market 2014-2019
  • Global A1PI market 2014-2019

PART 09:Market segmentation by disease type

  • Clotting disorders
  • Immune disorders
  • AATD
  • Others

PART 10:Geographical segmentation

PART 11:Market drivers

PART 12:Impact of drivers

PART 13:Market challenges

PART 14:Impact of drivers and challenges

PART 15:Market trends

PART 16:Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 17:Key vendor analysis

  • Baxter International Inc.
  • CSL Behring
  • Grifols
  • Octapharma

PART 18:Appendix

  • List of abbreviation

List of Exhibits:

  • Exhibit 01: Product offerings
  • Exhibit 02: Composition of blood
  • Exhibit 03: Composition of plasma
  • Exhibit 04: Total collection of plasma in US 2010-2014 (in liters)
  • Exhibit 05: Projected fractionation capacity of manufacturing units in US and EU (millions of liter/annum)
  • Exhibit 06: Process of procurement and manufacturing of plasma therapeutics
  • Exhibit 07: Regulatory policies of plasma protein therapy lifecycle
  • Exhibit 08: Global plasma therapeutics market 2014-2019 ($ billions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global plasma therapeutics market segment by fractionation products of plasma
  • Exhibit 11: Global human albumin market 2014-2019 ($ millions)
  • Exhibit 12: Key performance indicators of global albumin market
  • Exhibit 13: Global immunoglobulins market 2014-2019 ($ millions)
  • Exhibit 14: Key performance indicators of global immunoglobulin market
  • Exhibit 15: Global A1PI market 2014-2019 ($ millions)
  • Exhibit 16: Key performance indicators of global A1PI market
  • Exhibit 17: Global plasma therapeutics market segment by disease type
  • Exhibit 18: Segmentation of global plasma therapeutics market by geography 2014
  • Exhibit 19: Drivers of global plasma therapeutics market
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Challenges of global plasma therapeutics market
  • Exhibit 22: Impact of drivers and challenges
  • Exhibit 23: Global plasma therapeutics market share analysis 2014
  • Exhibit 24: YoY growth and revenue generated by plasma therapeutics 2011-2014 ($ millions)
  • Exhibit 25: YoY growth and revenue generate 2011-2014 ($ millions)
  • Exhibit 26: YoY growth and revenue of bioscience division 2011-2014 ($ millions)
  • Exhibit 27: Share of revenue by different divisions in 2014
  • Exhibit 28: YoY growth and revenue of plasma therapeutics 2011-2014 ($ millions)
  • Exhibit 29: Baxter International Inc. : Business segmentation
  • Exhibit 30: Baxter International Inc.: Revenue by business segmentation 2013
  • Exhibit 31: Baxter International Inc.: Revenue by geographical segmentation 2013
  • Exhibit 32: CSL Behring: Therapeutic areas segmentation 2013
  • Exhibit 33: CSL Behring: Product portfolio
  • Exhibit 34: CSL Behring: Geographical segmentation by revenue 2013
  • Exhibit 35: Grifols: Business segmentation by revenue 2013
  • Exhibit 36: Grifols: Business segmentation by revenue 2012 and 2013 ($ billions)
  • Exhibit 37: Grifols: Geographical segmentation by revenue 2013
  • Exhibit 38: Octapharma: Product offerings
Back to Top